How Joan, Hobbs Gabriela
Department of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Cancers (Basel). 2020 Jul 18;12(7):1954. doi: 10.3390/cancers12071954.
Interferon alfa was first used in the treatment of myeloproliferative neoplasms (MPNs) over 30 years ago. However, its initial use was hampered by its side effect profile and lack of official regulatory approval for MPN treatment. Recently, there has been renewed interest in the use of interferon in MPNs, given its potential disease-modifying effects, with associated molecular and histopathological responses. The development of pegylated formulations and, more recently, ropeginterferon alfa-2b has resulted in improved tolerability and further expansion of interferon's use. We review the evolving clinical use of interferon in essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF). We discuss interferon's place in MPN treatment in the context of the most recent clinical trial results evaluating interferon and its pegylated formulations, and its role in special populations such as young and pregnant MPN patients. Interferon has re-emerged as an important option in MPN patients, with future studies seeking to re-establish its place in the existing treatment algorithm for MPN, and potentially expanding its use for novel indications and combination therapies.
30多年前，干扰素α首次用于治疗骨髓增殖性肿瘤（MPN）。然而，其最初的使用受到副作用以及缺乏MPN治疗官方监管批准的阻碍。最近，鉴于干扰素在MPN中具有潜在的疾病修饰作用以及相关的分子和组织病理学反应，人们对其在MPN中的使用重新产生了兴趣。聚乙二醇化制剂的开发以及最近的罗培干扰素α-2b的出现，提高了耐受性并进一步扩大了干扰素的应用范围。我们回顾了干扰素在原发性血小板增多症（ET）、真性红细胞增多症（PV）和骨髓纤维化（MF）中不断发展的临床应用。我们结合评估干扰素及其聚乙二醇化制剂的最新临床试验结果，讨论干扰素在MPN治疗中的地位，以及它在年轻和妊娠MPN患者等特殊人群中的作用。干扰素已重新成为MPN患者的重要选择，未来的研究旨在重新确立其在MPN现有治疗方案中的地位，并可能扩大其在新适应症和联合治疗中的应用。
